The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary fibrosis
Publications
Pulmonary fibrosis induced by cyclophosphamide.
The Annals of pharmacotherapy 2001 Jul-Aug;35;894-7 — 2001 Jul-Aug — 894-7
Lung toxicity associated with cyclophosphamide use. Two distinct patterns.
American journal of respiratory and critical care medicine 1996 Dec;154;1851-6 — 1996 Dec — 1851-6
Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report.
Oncology 1983;40;174-6 — 1983 — 174-6
Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide.
British medical journal (Clinical research ed.) 1982 Sep 11;285;696 — 1982 Sep 11 — 696
Interstitial pneumonia after prolonged treatment with cyclophosphamide.
The American review of respiratory disease 1973 Jul;108;114-7 — 1973 Jul — 114-7
Progressive pulmonary fibrosis complicating cyclophosphamide therapy.
Acta medica Scandinavica 1987;221;403-7 — 1987 — 403-7
Pulmonary, pleural and thoracic changes complicating chemotherapy.
Radiology 1977 Dec;125;805-9 — 1977 Dec — 805-9
Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy.
Cancer 1979 May;43;1607-12 — 1979 May — 1607-12
Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.
The Journal of pediatrics 1978 Mar;92;443-6 — 1978 Mar — 443-6